Differing effects of low-dose estrogen–progestin therapy and pravastatin in postmenopausal hypercholesterolemic women

References

• Gerhard M, Ganz P. How do we explain the clinical benefits of estrogen? Circulation 1995; 92:5–8
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disaease. N Engl J Med 1996;335:453–61
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardio-vascular disease. Ann Intern Med 2000;133: 933–41
   PubMed Web of Science ®Google Scholar
• Mattsson L-A. Clinical experience with trans-dermal continuous combined HRT. Gynecol Endocrinol 1998;12:25–8
   Google Scholar
• Genant H, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy, effects on bone, plasma estradiol concentrations, endometrium, and lipids levels. Arch Intern Med 1997;157: 2609–15
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeiffer MA, Lemuel AM. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001–9
   Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9
   PubMed Web of Science ®Google Scholar
• The Lipid Study Group. Prevention of cardio-vascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–57
   PubMed Web of Science ®Google Scholar
• Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simva-statin for hypercholesterolemia in postmeno-pausal women. N Engl J Med 1997;337:595–601
   PubMed Web of Science ®Google Scholar
• Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves endothelium-dependent, flow mediated vasodilation in postmenopausal women. Ann Intern Med 1994;121:936–41
   PubMed Web of Science ®Google Scholar
• Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelial-dependent coronary vasomotor repsonsiveness in postmenopausalwomen with and without estrogen replacement therapy. Am J Cardiol 1994;73:951–2
   PubMed Web of Science ®Google Scholar
• Anderson TJ, Uehata A, Gerhard MD, et al. Close correlation of endothelial function in the human coronary and peripheral circulation. J Am Coll Cardiol 1995;26:1235–41
   PubMed Web of Science ®Google Scholar
• Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 1987;114: 413–19
   PubMed Web of Science ®Google Scholar
• Lindhal B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long term mortality in unstable coronary artery disease. N Engl J Med 2000;343:1139–47
   Google Scholar
• Koh KK, Mincemoyer R, Bui MN, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336:683–90
   PubMed Web of Science ®Google Scholar
• Australian Health Insurance Commission. Phar-maceutical Benefits Schedule Item Statistics. Canberra: Australian Federal Government, 13 March 2001
   Google Scholar
• Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499–502
   Google Scholar
• Sirridge MS, Shannon R. Laboratory Evaluation of Haemostasis and Thrombosis. Philadelphia: Lea and Febiger, 1983:163
   Google Scholar
• New G, Timmins KL, Duffy SJ, et al. Long-term estrogen therapy improves vascular function in male to female transsexuals. J Am Coll Cardiol 1997;29:1437–44
   PubMed Web of Science ®Google Scholar
• Hawthorn G, Richardson J, Osborne R, McNeil H. Australian Quality of Life Questionnaire. Centre for Health Programs and Evaluations, 1997. http://buseco.monash.edu.au/pubs/wp66
   Google Scholar
• The EuroQoL Group. EuroQol — a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208
   PubMed Web of Science ®Google Scholar
• Hunter M. The Women's Health Questionnaire: a measure of mid-aged women's perceptions of their emotional and physical health. Psychol Health 1992;7:45–54
   Web of Science ®Google Scholar
• Division of Metabolic and Endocrine Drug Products, Food and Drug Administration. Guide-lines for the Clinical Evaluation of Lipid-Lowering Agents in Adults and Children. Washington, DC: FDA, 1990
   Google Scholar
• The Writing Group for the Postmenopausal Estrogen/Progestin Interventions Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. J Am Med Assoc 1995;273:199–208
   Google Scholar
• Hulley S, Grady D, Bush T, et al. Heart and Estrogen/progestin Replacement Study Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1996;280:605–12
   Google Scholar
• Koh KK, Cardillo C, Bui MN, et al. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmeno-pausal women. Circulation 1999;99:354–60
   PubMed Web of Science ®Google Scholar
• Davidson MH, Testolin LM, Maki KC, von Duvillard S, Drennan KB. A comparison of estogen replacement, pravastatin, and combined treatment for the management of hypercholester-olemia in postmenopausal women. Arch Intern Med 1997;157:1186–92
   Google Scholar
• Denke MA. Effects of continuous combined hormone replacement therapy on lipid levels in hypercholestolemic postmenopausal women. Am J Med 1995;99:29–35
   PubMed Web of Science ®Google Scholar
• Granfone A, Campos H, McNamara JR. Effects of oestrogen replacement on plasma lipoproteinsand apolipoproteins in postmenopausal dyslipidemic women. Metabolism 1992;41: 1193–8
   Google Scholar
• Shlipak M, Simon J, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a) and the risk of recurrent coronary heart disease after meno-pause. J Am Med Assoc 2000;283:1845–52
   PubMed Web of Science ®Google Scholar
• Farish E, Fletcher CD, Dagen MM. Lipoprotein and apolipoprotein levels in postmenopausal women on continuous oestrogen/progestogen therapy. Br J Obstet Gynaecol 1989;96:358–64
   Google Scholar
• Celemajer DS, Sorensen K, Gooch V, et al. Non-invasive detection of endothelial dysfunc-tion in children and adults at risk of atherosclero-sis. Lancet 1992;340:1111–15
   PubMed Web of Science ®Google Scholar
• Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothe-lial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function on the endothelium trial). Circulation 1999;99:3227–33
   Google Scholar
• Cohen JD, Drury JH, Ostdiek J, et al. Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average choles-terol levels: a mechanism for reducing clinical events? Am Heart J 2000;139:734–8
   PubMed Web of Science ®Google Scholar
• Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981–3
   Google Scholar